Incidence and Visual Outcomes of Endophthalmitis After Intravitreal Injection of Dexamethasone Implant vs Ranibizumab
| Autor: | Maitri Pancholy, Philip P. Storey, Edward H. Wood, Varun Chaudhary, Anthony Obeid, Elizabeth Marlow, Nathan D. Farley, Jeremy D. Wolfe, Sunir J. Garg |
|---|---|
| Rok vydání: | 2022 |
| Zdroj: | Journal of VitreoRetinal Diseases. 6:358-366 |
| ISSN: | 2474-1272 2474-1264 |
| DOI: | 10.1177/24741264221109376 |
| Popis: | Purpose: To compare the incidence and visual outcomes of endophthalmitis after injection of an intravitreal dexamethasone implant and injection of intravitreal ranibizumab. Methods: This retrospective cohort study assessed endophthalmitis in eyes receiving an intravitreal injection of a 0.7 mg dexamethasone implant (DEX group), 0.5 mg ranibizumab (R5 group), or 0.3 mg ranibizumab (R3 group) between January 1, 2016, and May 31, 2018, at 2 large retina practices in the United States. Results: Suspected endophthalmitis occurred in 5 eyes after 4973 DEX injections, 43 eyes after 163 974 R5 injections, and 6 eyes after 18 954 R3 injections. Suspected endophthalmitis was significantly more common in the DEX group (1/995) than in the R5 group (1/3813) ( P = .008) but not than in the R3 group (1/3159) ( P = .10). Visual acuity outcomes were similar in the 3 groups. Conclusions: Suspected endophthalmitis might be more common after 0.7 mg dexamethasone injections than after 0.5 mg ranibizumab injections. Culture-positive endophthalmitis rates were similar across all 3 medications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|